Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 7, 2010 Brian Orelli	How Pfizer's New Chief Can Right the Ship Bigger is not always better.
BusinessWeek October 31, 2008 Arlene Weintraub	Pfizer CEO Kindler Has His Work Cut Out for Him Investors want a fresh perspective for post-Lipitor Pfizer, but they're not yet convinced outsider CEO Jeffrey Kindler is the one to bring it.
Chemistry World April 6, 2011 Andrew Turley	Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'.
BusinessWeek August 14, 2006 Arlene Weintraub	The Lawyer Is In At Pfizer Jeffrey Kindler's ascent reflects the new challenges drugmakers face.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool January 5, 2009 Brian Orelli	Pfizer Goes Shopping and Water Is Wet: News at 11! In an interview with the Financial Times, Pfizer's CEO Jeff Kindler said the company is willing to buy another company.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur.
Pharmaceutical Executive July 1, 2006 Ron Feemster	Good Counsel Law the Pfizer way: Crack down on counterfeiters, build a private police force, and make nice with the Office of the Inspector General. Then hire a foreign-policy expert.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool February 2, 2010 Brian Orelli	Foolish Forecast: First Look at Pfizer Plus With the addition of Wyeth last quarter, there's no doubt Pfizer is larger, but whether that bigger size translates into savings that boosts profits remains to be seen.
Chemistry World January 27, 2009 Matt Wilkinson	Pfizer's Wyeth injection Pfizer has agreed to pay $68 billion ( 48.3 billion) for rival US biopharmaceutical firm Wyeth, gaining access to its rich product portfolio and promising pipeline of experimental drugs.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool June 19, 2008 Brian Lawler	Pfizer's Small Lipitor Win Pfizer and the most prolific challenger of its Lipitor patents, Indian generic-drug manufacturer Ranbaxy, settle the vast majority of their litigation.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
CIO October 28, 2011 Kim S. Nash	Challenging Times for Pfizer As drug patents expire, the pharmaceutical giant is investing in technology and emerging markets while cutting back on R&D and labor.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
Pharmaceutical Executive March 1, 2007 Beth Herskovits	If I Ran Pfizer The industry is at a crossroads, and all eyes are on the world's largest drug maker. When Pfizer leads, others follow. So we asked: If you had that sort of influence, how would you steer Big Pharma?
BusinessWeek January 10, 2005 Amy Barrett	Pfizer Has Plenty Of Pain To Kill Many investors and analysts argue that while the drug company should continue to plow money into new-drug development, the company needs to aggressively reduce other costs and return greater amounts of cash to shareholders through a higher dividend.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
Chemistry World February 1, 2013 Andrew Turley	Zoetis IPO launches at $2.2bn The separation of Pfizer from its animal health business, Zoetis, has begun. Pfizer has priced its initial public offering of 86 million shares at $26 per share, for a total of $2.2 billion
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool July 24, 2008 Brian Lawler	Will Pfizer Pfizzle? The drugmaker posts strong earnings, but the good times may not last.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
Chemistry World February 2, 2007 Victoria Gill	AstraZeneca Follows Pfizer in Slashing Workforce The Anglo-Swedish pharmaceutical hopes that by streamlining its operation it can offset the growing financial threat from cheap generic copies of its best-selling blood pressure drug. Nevertheless, the company has reported unexpectedly cheerful fourth quarter profits.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool August 25, 2008 Rich Duprey	Lipitor Marketing Raises Blood Pressure Pfizer continues affinity-group marketing of its best-selling cholesterol drug Lipitor.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
The Motley Fool April 4, 2011 Brian Orelli	Pfizer Tests the Breakup Waters The company announced today that it found a buyer for its Capsugel unit, which will bring in a cool $2.4 billion.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool January 24, 2008 Brian Lawler	Pfiltering Through Pfizer's Year Pfizer releases its 2007 numbers, displaying year-over-year earnings growth powered by foreign currency gains.